A Phase 3 interventional study of Liraglutide and Placebo in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 32 sites in 9 countries. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.
Among the 79 studies testing liraglutide in Obesity, this one is the 32nd largest by enrollment, is one of 5 that started in 2021, is one of 17 in phase 3, and was the 66th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Brigham and Women's Hospital · Sites in South Africa
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–70
Emirates Health Services (EHS) · Sites in United Arab Emirates
Ages 22–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 18 · Phase 4 37
First in 2007; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 70 across the 79 interventional studies. Of the 54 that completed or were terminated, 24 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 79 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 113th largest by enrollment of the 166 interventional ones that give a count, is one of 10 that started in 2021, is one of 62 in phase 3, reaches primary completion later than 0 of the 65 other live ones, and was the 71st registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
2 of the studies testing liraglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT02944500Beth Israel Deaconess Medical CenterSaxenda: Underlying Mechanisms and Clinical Outcomes | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies testing liraglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects.
Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day.
In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight.
The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For subjects with type 2 diabetes at screening the following inclusion criterion apply in addition:
- (HbA1c) below or equal to 10.0 percent (86 mmol/mol) as measured by central laboratory at screening
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The treatment duration is 56 weeks and the follow-up period is 26 weeks.
Drug: Liraglutide
The treatment duration is 56 weeks and the follow-up period is 26 weeks.
Drug: Placebo
The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily. The dose will increase each week over 4 or 5 weeks until the final dose is reached.
The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
Relative Change in Body Mass Index (BMI)
Relative change in BMI from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
Time frame: Baseline (week 0), week 56
Relative Change in Body Weight (Percentage)
Relative change in body weight (Percentage) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
Time frame: Baseline (week 0), week 56
Percentage of Participants Achieving More Than or Equal to (≥) 5% Reduction of BMI
Percentage of participants who achieved more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 56 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 56 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 56. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
Time frame: At week 56
Change in Body Weight (Kilogram)
Change in body weight (Kilogram) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
Time frame: Baseline (week 0), week 56
Change in BMI Standard Deviation Score (WHO.Int)
Change in BMI SDS (BMI-for-age-and-sex Z-score) was calculated as the Week 56 score minus the baseline (Week 0) score. BMI Z-scores were calculated using World Health Organization (WHO) age- and sex-specific reference values and the formula Z=\[(BMI/M)\^L-1\]/(L×S), where M is the median BMI, L is the Box-Cox power accounting for skewness, and S is the coefficient of variation. A BMI Z-score of 0 represents the age- and sex-specific population mean. According to the WHO growth reference, BMI-for-age values greater than (\>) +1 SD and \>+2 SD correspond approximately to overweight and obesity, respectively. Positive Z-scores indicate BMI SDS values above the age- and sex-specific population mean, whereas negative Z-scores indicate values below the age- and sex-specific population mean. For change from baseline, negative values indicate a decrease in BMI SDS (favourable outcome), positive values indicate an increase in BMI SDS (unfavourable outcome), and 0 indicates no change.
Time frame: Baseline (week 0), week 56
Percentage of Participants Achieving ≥10% Reduction of BMI
Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 56 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 56 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 56. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
Time frame: At week 56
Change in BMI Percentage of the 95th Percentile on Gender and Age-specific Growth Charts (CDC.Gov [CDC: {Centers for Disease Control and Prevention}])
Change in BMI percentage of the 95th percentile on gender and age-specific growth charts (CDC.gov) from baseline (week 0) to week 56 is presented. CDC gender and age-specific growth charts: normal (BMI less than \[\<\] 85th percentile), overweight (BMI greater than or equal to \[\>=\] 85th - \<95th percentile), obesity class I (BMI \>=95th - \<120% of the 95th percentile), obesity class II (BMI \>=120% of the 95th percentile - \<140% of the 95th percentile) and obesity class III (BMI \>=140% of the 95th percentile). The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
Time frame: Baseline (week 0), week 56
Change in Waist Circumference
Change in waist circumference from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
Time frame: Baseline (week 0), week 56
Change in Systolic Blood Pressure
Change in systolic blood pressure from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
Time frame: Baseline (week 0), week 56
Change in Diastolic Blood Pressure
Change in diastolic blood pressure from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
Time frame: Baseline (week 0), week 56
Change in Glycated Haemoglobin (HbA1c)
Change in glycated haemoglobin (HbA1c) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
Time frame: Baseline (week 0), week 56
Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or using a medicinal product, whether or not considered related to the medicinal product or usage. The endpoint was evaluated based on the data from On-treatment period which was defined as events with onset date between the first day of study product administration and whatever comes first: a) 14 days after the last day on study product, b) first follow up visit (V24 for participants with study product discontinued), or c) last study visit (participants withdrawn without follow-up visit).
Time frame: From baseline (week 0) to week 82
Treatment Emergent Serious Adverse Events (SAEs)
An SAE is an AE that fulfils at least one of the following criteria: 1) results in death; 2) is life-threatening; 3) requires inpatient hospitalisation or prolongation of existing hospitalisation; 4) results in persistent disability/incapacity; 5) is a congenital anomaly/birth defect; 6) important medical event. The endpoint was evaluated based on the data from On-treatment period which was defined as events with onset date between the first day of study product administration and whatever comes first: a) 14 days after the last day on study product, b) first follow up visit (V24 for participants with study product discontinued), or c) last study visit (participants withdrawn without follow-up visit).
Time frame: From baseline (week 0) to week 82
This trial was conducted at 25 sites that enrolled participants in Belgium, India, Israel, Malaysia, Mexico, Portugal, Russia, Switzerland and the United States.
| Milestone | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Started | 56 | 26 |
| Completed | 44 | 22 |
| Not completed | 12 | 4 |
| Withdrew: Other | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Technical problems | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Adverse event | 6 | 0 |
Relative change in BMI from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
| Percentage (%) change of BMI | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Relative Change in Body Mass Index (BMI) | -6.7 ± 9.6 | 2.1 ± 6.1 |
Relative change in body weight (Percentage) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
| Percentage (%) change of body weight | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Relative Change in Body Weight (Percentage) | 0.4 ± 10.7 | 10.2 ± 6.8 |
Percentage of participants who achieved more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 56 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 56 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 56. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
| Percentage (%) of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Yes | 46.2 | 8.7 |
| No | 53.8 | 91.3 |
Change in body weight (Kilogram) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
| Kilogram (kg) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Body Weight (Kilogram) | 0.1 ± 8.2 | 7.5 ± 5.3 |
Change in BMI SDS (BMI-for-age-and-sex Z-score) was calculated as the Week 56 score minus the baseline (Week 0) score. BMI Z-scores were calculated using World Health Organization (WHO) age- and sex-specific reference values and the formula Z=\[(BMI/M)\^L-1\]/(L×S), where M is the median BMI, L is the Box-Cox power accounting for skewness, and S is the coefficient of variation. A BMI Z-score of 0 represents the age- and sex-specific population mean. According to the WHO growth reference, BMI-for-age values greater than (\>) +1 SD and \>+2 SD correspond approximately to overweight and obesity, respectively. Positive Z-scores indicate BMI SDS values above the age- and sex-specific population mean, whereas negative Z-scores indicate values below the age- and sex-specific population mean. For change from baseline, negative values indicate a decrease in BMI SDS (favourable outcome), positive values indicate an increase in BMI SDS (unfavourable outcome), and 0 indicates no change.
| Z-score | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in BMI Standard Deviation Score (WHO.Int) | -0.78 ± 0.58 | -0.34 ± 0.33 |
Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 56 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 56 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 56. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
| Percentage (%) of participants | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Yes | 34.6 | 4.3 |
| No | 65.4 | 95.7 |
Change in BMI percentage of the 95th percentile on gender and age-specific growth charts (CDC.gov) from baseline (week 0) to week 56 is presented. CDC gender and age-specific growth charts: normal (BMI less than \[\<\] 85th percentile), overweight (BMI greater than or equal to \[\>=\] 85th - \<95th percentile), obesity class I (BMI \>=95th - \<120% of the 95th percentile), obesity class II (BMI \>=120% of the 95th percentile - \<140% of the 95th percentile) and obesity class III (BMI \>=140% of the 95th percentile). The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
| % change in BMI% of the 95th percentile | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in BMI Percentage of the 95th Percentile on Gender and Age-specific Growth Charts (CDC.Gov [CDC: {Centers for Disease Control and Prevention}]) | -15.1 ± 12.9 | -3.4 ± 7.4 |
Change in waist circumference from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
| Centimeter (cm) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Waist Circumference | -1.89 ± 8.34 | 3.06 ± 7.74 |
Change in systolic blood pressure from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
| Millimeters of mercury (mmHg) | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Systolic Blood Pressure | -2 ± 10 | 0 ± 13 |
Change in diastolic blood pressure from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
| mmHg | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Diastolic Blood Pressure | -1 ± 10 | 0 ± 10 |
Change in glycated haemoglobin (HbA1c) from baseline (week 0) to week 56 is presented. The endpoint was evaluated based on the data from in-trial period which was defined as the uninterrupted time interval from date of randomisation to date of last contact with study site.
| Percentage change in HbA1c | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Change in Glycated Haemoglobin (HbA1c) | -0.2 ± 0.2 | 0.0 ± 0.2 |
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or using a medicinal product, whether or not considered related to the medicinal product or usage. The endpoint was evaluated based on the data from On-treatment period which was defined as events with onset date between the first day of study product administration and whatever comes first: a) 14 days after the last day on study product, b) first follow up visit (V24 for participants with study product discontinued), or c) last study visit (participants withdrawn without follow-up visit).
| Number of events | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Treatment Emergent Adverse Events (TEAEs) | 436 | 156 |
An SAE is an AE that fulfils at least one of the following criteria: 1) results in death; 2) is life-threatening; 3) requires inpatient hospitalisation or prolongation of existing hospitalisation; 4) results in persistent disability/incapacity; 5) is a congenital anomaly/birth defect; 6) important medical event. The endpoint was evaluated based on the data from On-treatment period which was defined as events with onset date between the first day of study product administration and whatever comes first: a) 14 days after the last day on study product, b) first follow up visit (V24 for participants with study product discontinued), or c) last study visit (participants withdrawn without follow-up visit).
| Number of events | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| Treatment Emergent Serious Adverse Events (SAEs) | 12 | 2 |
Collected over From baseline (week 0) to week 82. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide 3.0 mg | 0/56 (0%) | 7/56 (12.5%) | 47/56 (83.9%) |
| Placebo | 0/26 (0%) | 2/26 (7.7%) | 22/26 (84.6%) |
| Event | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| VomitingGastrointestinal disorders | 3/56 | 0/26 |
| Limb injuryInjury, poisoning and procedural complications | 0/56 | 1/26 |
| Suicide attemptPsychiatric disorders | 0/56 | 1/26 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/56 | 0/26 |
| ColitisGastrointestinal disorders | 1/56 | 0/26 |
| Dengue feverInfections and infestations | 1/56 | 0/26 |
| EpilepsyNervous system disorders | 1/56 | 0/26 |
| HeadacheNervous system disorders | 1/56 | 0/26 |
| MigraineNervous system disorders | 1/56 | 0/26 |
| NauseaGastrointestinal disorders | 1/56 | 0/26 |
| Event | Liraglutide 3.0 mg | Placebo |
|---|---|---|
| VomitingGastrointestinal disorders | 35/56 | 4/26 |
| NauseaGastrointestinal disorders | 25/56 | 5/26 |
| DiarrhoeaGastrointestinal disorders | 19/56 | 7/26 |
| COVID-19Infections and infestations | 11/56 | 6/26 |
| HeadacheNervous system disorders | 8/56 | 6/26 |
| ContusionInjury, poisoning and procedural complications | 4/56 | 5/26 |
| PyrexiaGeneral disorders | 5/56 | 5/26 |
| Abdominal pain upperGastrointestinal disorders | 10/56 | 4/26 |
| NasopharyngitisInfections and infestations | 9/56 | 2/26 |
| Abdominal painGastrointestinal disorders | 7/56 | 4/26 |
The full analysis set (FAS) included all randomised participants according to the intention-to-treat principle, i.e., participants were included according to planned treatment.
| Age, Continuous(Years) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Mean | 10 ± 2 | 10 ± 2 | 10 ± 2 |
| Sex: Female, Male(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Female | 26 | 12 | 38 |
| Male | 30 | 14 | 44 |
| Ethnicity (NIH/OMB)(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 1 | 11 |
| Not Hispanic or Latino | 46 | 25 | 71 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Liraglutide 3.0 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 6 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 37 | 22 | 59 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 8 | 0 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Mar 2021 to primary completion in Aug 2023, 28 months.
Results were first posted in Nov 2026, 3 years 3 months after primary completion. A results delay was requested in Jul 2024.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 28 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide